Individuals carrying the variant that binds glucokinase less effectively are indeed characterized by reduced fasting plasma glucose levels, but this is accompanied by an increased risk of nonalcoholic fatty liver disease (NAFLD), hypertriglyceridemia, and gout [12–14]. Here, GCK is linked to metabolic dysfunction-associated steatotic liver disease.